Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 or AK112 + Axitinib in Metastatic Mucosal Melanoma
NCT06424626Phase 1Enrolling by invitation
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- May 2024
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of cadonilimab and ivonescimab in mucosal melanoma (MM) (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Dose-Limiting Toxicity at 4 weeks and Treatment-Related Adverse Events at 3 years. Started May 2024; status: enrolling by invitation.
02
Drugs
cadonilimabivonescimab
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT06424626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06424626.